Insider Selling: ProKidney Corp. (NASDAQ:PROK) SVP Sells $43,095.00 in Stock

ProKidney Corp. (NASDAQ:PROK) SVP Darin J. Weber sold 17,238 shares of the business’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $2.50, for a total value of $43,095.00. Following the transaction, the senior vice president now owns 172,432 shares in the company, valued at approximately $431,080. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

ProKidney Stock Down 15.0 %

Shares of PROK opened at $2.04 on Friday. The business’s 50 day moving average price is $1.60 and its 200-day moving average price is $1.79. ProKidney Corp. has a 52 week low of $1.12 and a 52 week high of $13.51. The stock has a market cap of $467.85 million, a P/E ratio of -3.58 and a beta of 1.08.

ProKidney (NASDAQ:PROK) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.09) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. On average, equities analysts anticipate that ProKidney Corp. will post -0.65 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Morgan Stanley assumed coverage on ProKidney in a report on Thursday, March 7th. They set an “equal weight” rating and a $3.00 price target on the stock. Bank of America cut ProKidney from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 2nd.

Institutional Trading of ProKidney

Hedge funds have recently made changes to their positions in the stock. Lazard Asset Management LLC bought a new stake in shares of ProKidney in the 2nd quarter worth approximately $31,000. Tower Research Capital LLC TRC lifted its position in ProKidney by 98.5% in the 1st quarter. Tower Research Capital LLC TRC now owns 4,456 shares of the company’s stock valued at $50,000 after acquiring an additional 2,211 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in ProKidney in the 2nd quarter valued at approximately $57,000. UBS Group AG lifted its position in ProKidney by 97.5% in the 1st quarter. UBS Group AG now owns 5,209 shares of the company’s stock valued at $59,000 after acquiring an additional 2,571 shares in the last quarter. Finally, Royal Bank of Canada lifted its position in ProKidney by 530.3% in the 2nd quarter. Royal Bank of Canada now owns 6,965 shares of the company’s stock valued at $78,000 after acquiring an additional 5,860 shares in the last quarter. 51.59% of the stock is owned by institutional investors.

About ProKidney

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.